Espinosa-Cárdenas R, Arce-Sillas A, Álvarez-Luquin D, Leyva-Hernández J, Montes-Moratilla E, González-Saavedra I, Boll MC, Garcia-Garcia E, Ángeles-Perea S, Fragoso G, Sciutto E, Adalid-Peralta L. Immunomodulatory effect and clinical outcome in Parkinson's disease patients on levodopa-pramipexole combo therapy: A two-year prospective study. J Neuroimmunol 2020;347:577328. [PMID: 32721557 DOI: 10.1016/j.jneuroim.2020.577328][Cited by in Crossref: 2][Cited by in F6Publishing: 2][Article Influence: 1.0][Reference Citation Analysis]
Number
Citing Articles
1
Álvarez-Luquín DD, Guevara-Salinas A, Arce-Sillas A, Espinosa-Cárdenas R, Leyva-Hernández J, Montes-Moratilla EU, Adalid-Peralta L. Increased Tc17 cell levels and imbalance of naïve/effector immune response in Parkinson's disease patients in a two-year follow-up: a case control study. J Transl Med 2021;19:378. [PMID: 34488776 DOI: 10.1186/s12967-021-03055-2][Reference Citation Analysis]
2
Jiang DQ, Zang QM, Jiang LL, Wang Y, Li MX, Qiao JY. Comparison of pramipexole and levodopa/benserazide combination therapy versus levodopa/benserazide monotherapy in the treatment of Parkinson's disease: a systematic review and meta-analysis. Naunyn Schmiedebergs Arch Pharmacol 2021;394:1893-905. [PMID: 33959780 DOI: 10.1007/s00210-021-02089-z][Reference Citation Analysis]
